Pharmaceutical Supply Shortages Are A Growing Risk, Report Warns


The report from the American Society of Health-system Pharmacists says covid, trade restrictions, technology failures or breaches could cause widespread disruptions in delivery.

Drug Supply Chain Issues Aren’t Going Away, Report Says 

In a new American Society of Health-system Pharmacists (ASHP) report, 92% of its “2021 Pharmacy Forecast” panelists say global issues like trade restrictions, pandemics like COVID-19, or climate change will increase the potential for more drug shortages, and almost 90% say a major technology failure or breach could cause widespread disruptions in the delivery of US healthcare supplies. To help mitigate these issues, 90% of panelists also predicted that at least 75% of health systems will develop allocation guidelines. In the report, the ASHP notes a 36.6% increase in ongoing drug shortages from 2017 to 2020, with 276 shortages occurring in 2020. (McLernon, 2/22)

In other pharmaceutical and research news —

FDA Concludes Brainstorm’s Cell Therapy For ALS Lacks Convincing Data

The Food and Drug Administration told Brainstorm Therapeutics that rejiggered data from a negative clinical trial does not support the submission of a stem cell therapy for patients with amyotrophic lateral sclerosis, or Lou Gehrig’s disease, the company said Monday. Despite the FDA’s recommendation that Brainstorm not seek the approval of its patient-specific ALS treatment called NurOwn, the company may still do so, but will consult with outside experts first before making a decision. (Feuerstein, 2/22)

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Source link